The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Olanzapine: evaluation of the in vivo cytogenetic effect.

TitleOlanzapine: evaluation of the in vivo cytogenetic effect.
Publication TypeJournal Article
Year of Publication2015
AuthorsConstantinos, Z., Eleni P., Goulas A., & Iakovidou-Kritsi Z.
JournalHum Psychopharmacol
Volume30
Issue3
Pagination189-92
Date Published2015 May
ISSN1099-1077
KeywordsAdult, Antipsychotic Agents, Benzodiazepines, Case-Control Studies, Cell Proliferation, Cytogenetic Analysis, Humans, Lymphocytes, Male, Schizophrenia, Sister Chromatid Exchange, Smoking
Abstract

BACKGROUND/AIMS: Olanzapine (OLZ), an atypical antipsychotic, is licensed for use in the treatment of schizophrenia and other psychiatric disorders.METHODS: OLZ cytogenetic effects were investigated by evaluating the frequency of Sister Chromatid Exchanges (SCEs) and Proliferation Rate Index (PRI) in cultured lymphocytes of schizophrenic patients who were under treatment of OLZ. SCE estimation is one of the most sensitive biomarkers of potential cytotoxicity, while PRI is used as a valuable marker of cytostatic activity.RESULTS: Our results showed a statistically significant increase of SCEs in the cultured lymphocytes of patients (p < 0,001) compared to the lymphocytes of healthy donors, a statistically significant increase of SCEs (p < 0.001) in the lymphocytes of smoker patients compared to those of non-smoker patients and a statistically significant increase of SCEs (p < 0.001) in the lymphocytes of chronic recipients of OLZ compared to those of the patients with recent initiation of treatment. We did not detect any statistically significant differences with respect to PRI between the various groups examined.CONCLUSIONS: Our results indicate a mild cytotoxic-but not cytostatic-effect of OLZ which was more prominent in smokers and in chronically treated patients. That effect should be taken into consideration by psychiatrists upon assessing the benefit/risk ratio of their prescriptions.

DOI10.1002/hup.2471
Alternate JournalHum Psychopharmacol
PubMed ID25787772

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.